Skip to main content
OpenTrials
Completed

NCT Number: NCT04406454

The Application of Non-invasive and Cellular Level Resolution Fullfield Optical Coherence Tomography: Establishment and Analysis of Subcutaneous Cellular Level Image Database of Anatomical Locations in Healthy Volunteers and Evaluation of Usability

ApolloVue® S100 Image System is a medical device class II. The objective of this protocol is to image skin of healthy volunteers and to evaluate the performance of full-field optical coherence tomography (FF-OCT) device - the ApolloVue® S100 Image System in imaging skin microstructures of healthy skin at different anatomical locations and nevi for different skin types and different age and to evaluate usability of the ApolloVue® S100 Image System.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Taipei Veterans General Hospital

Taipei, Beitou District, 11217, Taiwan

About this study

The OCT can provide cellular resolution (~1μm in lateral and axial directions) images. A cellular resolution OCT has the characteristics of non-invasive, non-radioactive, labelfree, real-time and high tissue penetration depth that are highly valuable for clinical use. This technology allows visualization of important structural features such as the epidermis and dermis and the epidermal-dermal junction. OCT has the advantage of generating cross-sectional images, like the orientation of pathology slides.

The ApolloVue® S100 Image System is intended to be used as a non-invasive imaging tool in the evaluation of external human skin tissue microstructure by providing two-dimensional, crosssectional (B-scan) and en face (E-scan) real-time visualization for assessment by physicians to support in forming a clinical judgment. For the ApolloVue® S100 Image System image, both cross-sectional view and en face view can be obtained to assist physicians' diagnosis. With both views, physicians can obtain important spatial information in regards to the skin. Besides, the ApolloVue® S100 Image System is equipped with an image guiding system which provides a high-resolution dermatoscope like image, for the positioning of skin sites for optical biopsies.

In this protocol, it is proposed to study the optical imaging features of healthy human skin and nevi and the evaluation of usability. We propose to recruit 60 subjects for such a trial. Healthy volunteers will be approached and consented to this protocol. The volunteers will be imaged.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All age will be recruited.
  • Both genders will be recruited.
  • All skin types will be recruited. Skin type I-VI (Fitzpatrick scale)
  • Type I always burns, never tans (unexposed skin color: white)
  • Type II usually burns, tans less than average (with difficulty) (unexposed skin color: white)
  • Type III sometimes mild burns, tans about average (unexposed skin color: white)
  • Type IV rarely burns, tans more than average (with easy) (unexposed skin color: white)
  • Type V very rarely burns (unexposed skin color: brown)
  • Type VI never burns (unexposed skin color: black)
  • Has healthy skin at 5 anatomical locations including face, back, dorsal forearm, volar forearm, and calf.
  • Has at least a nevus without superficial scales and crusting
  • Willing to provide informed consent

Exclusion criteria

  • Individuals who have a systemic skin disorder.
  • Individuals who have a history of severe skin condition
  • Individuals with surgeries/cosmetic surgeries/micro cosmetic surgery (eg. cosmetic injections and/or laser etc.) on healthy skin at the 5 anatomical locations and nevi (see inclusion criteria 5) in last 12 months and a physician determine the surgery will affect outcome of the OCT images.
  • Not willing to cooperate with methods and related procedures of this trial/study

Treatment and study plan

ApolloVue® S100 Image System

Device

The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.

Primary outcomes

  1. Determine the average scanning success rate of obtaining at least 3 quality OCT images of B-scan and E-scan with 4 depths for each skin site, respectively.

    Time frame: 2 years

    • Scanning efficiency = total number of quality images/total number of images obtained x 100%.
    • Scanning efficiency ≧ 50%
  2. Evaluator identification of each feature will be assessed (number of correctly identified feature/number of total features x 100%).

    Time frame: 2 years

    The purpose of this evaluation is to validate that the ApolloVue® S100 Image System delivers non-invasive skin image features.

    Required features will be analyzed for each group, including age, skin type and anatomical location.

    The features need to meet the following requirement in each 500 x 400 µm2 image for B-scan and in each 500 x 500 μm2 image for E-scan.

    A. Identification of keratinocyte in ≧ 80% of images (B-scan only)

    B. Identification of stratum corneum in ≧ 80% of images

    C. Identification of epidermis in ≧ 80% of images

    D. Identification of dermis in ≧ 80% of images

    E. Identification of EDJ in ≧ 80% of images

    F. Identification of collagen in ≧ 80% of images (B-scan only)

    G. Identification of melanin in ≧ 80% of images

  3. Determine time required to obtain at least 3 quality OCT images of B-scan and E-scan with 4 depths for each skin site, respectively.

    Time frame: 2 years

    Time required < 20 minutes for each body site except for nevus.

    Time required < 40 minutes for a nevus including image guiding.

Sponsors and collaborators

Lead sponsor

Taipei Veterans General Hospital, Taiwan

Other Gov

Collaborators

  • Apollo Medical Optics, Ltd

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
May 28, 2020
Registry last updated
Nov 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.